Israel Biotech Fund (IBF)

ibf.fund

Venture Capital Management Company

General Data

Established	2015
Current Active Portfolio Companies:	17
Reg. Number:	abCDe

DESCRIPTION

Israel Biotech Fund seeks high value returns by identifying and maximizing the success of therapeutic assets of Israel-based biotech companies. Based in Rehovot, Israel’s main Biotech hub, the fund invests exclusively in Biotech companies developing drugs at or near clinical stages. The team provides portfolio companies with the necessary resources for long-term sustainable growth. This approach enhances their value and the investor’s long-term capital appreciation, while strengthening Israel’s Biotech industry which increases investment opportunities. The biotechnology industry in Israel is growing with enormous potential and IBF is determined to realize its full potential and real value.

Managed Funds

Fund Name	Fund Capital($m)	Status	Remarks
Israel Biotech Fund I	abCDe	Fully invested
Israel Biotech Fund II	abCDe	Final Closing

REMARKS

Date	Remark
01/10/2021	October 2021, Launch of AION Labs, an innovation lab spearheading the adoption of AI technologies and computational science to solve therapeutic challenges, formed by Pfizer, AstraZeneca, Merck, and Teva together with IBF and Amazon.

CONTACT INFO

Expand / Collapse All

Main Address: Rehovot, Israel

Address	HaOgen B Tower, 4 Oppenheimer St
City	Rehovot
Country	Israel
Zip	7670104

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

	MANAGEMENT

Key Executive

Name	Title
Mr. Ido Zairi	Managing Partner & Co-Founder
Dr. Yuval Cabilly	Managing Partner & Co-Founder
Prof. David Sidransky	Managing Partner & Co-Founder
Ms. Sarit Steinberg	Partner

Investment Data

Managed Capital

abCDe

SECTOR SEGMENTATION (By Number Of Companies)

Biomed

81%

Medical Devices

13%

Digital Health

	PORTFOLIO COMPANIES

Current Portfolio Companies (17)

Company Name	Sector	Invested Fund	Remarks
4C Biomed	Biomed	abC Defghij
AION Labs	N/A	abC Defghij
AnserBio	Biomed	abC Defghij
Biond Biologics	Biomed	abC Defghij
Cassidy Bio	Biomed	abC Defghij
Cellyrix	MD	abC Defghij
Coltac	Biomed	abC Defghij
DenovAI Biotech	Dig. Health	abC Defghij
MediWound	Biomed	abC Defghij
Nectin	Biomed	abC Defghij
ProPhet	Biomed	abC Defghij
Renasis Bio	Biomed	abC Defghij
SpliSense	Biomed	abC Defghij
TenAces	Biomed	abC Defghij
TPCera	Biomed	abC Defghij
Ukko	Biomed	Israel Biotech Fund II
Vensica	MD	Israel Biotech Fund II

Exits (8)

Company Name	Sector	Exit Type	Date Announced	Amount
abC Defghij	Biomed	Acquired	19/01/2023	abCDe
abC Defghij	Biomed	IPO	07/05/2020	abCDe
abC Defghij	Biomed	Acquired	27/07/2023	abCDe
abC Defghij Investment Company	N/A	IPO	29/10/2021	abCDe
abC Defghij	Biomed	Acquired	12/01/2026	abCDe
abC Defghij	Biomed	Acquired	27/03/2024	abCDe
abC Defghij	Biomed	IPO	26/10/2018	abCDe
abC Defghij	Biomed	Holdings Sold	01/01/2019	abCDe

Historic Portfolio (4)

Company Name	Company Status	Sector	Invested Fund
MemoryPlus	Ceased to Operate	Biomed	Israel Biotech Fund II
Peles Therapeutics	Ceased to Operate	Biomed	Israel Biotech Fund II
Pharma Two B	Ceased to Operate	Biomed	Israel Biotech Fund I
Tamarix Pharma	Ceased to Operate	Biomed	Israel Biotech Fund II

Last Updated:	abCDe
IVC Number:	abCDe